Three types of hypoglycemic agents (Dipeptidyl peptidase-4 inhibitors, Glucagon-like peptide-1 receptor agonists, Sodium-dependent glucose transporters 2 inhibitors) for patients with type 2 diabetes: effectiveness and safety evaluation network meta-analysis

Three types of hypoglycemic agents (Dipeptidyl peptidase-4 inhibitors, Glucagon-like peptide-1 receptor agonists, Sodium-dependent glucose transporters 2 inhibitors) for patients with type 2 diabetes: effectiveness and safety evaluation network meta-analysis

According to the latest data released by the International Diabetes Federation (IDF) in 2019, there are currently 463 million diabetics among adults between 20 and 79 years old in the world. This data is expected to reach 578.4 million by 2030. Diabetes is now a major problem threatening human health,and a variety of hypoglycemic drugs have appeared in recent years. In view of the development of hypoglycemic agents and the growth in the number of people with type 2 diabetes mellitus(T2DM), latest information is needed for clinicians and patients to make more reliable decisions. We'd like to perform a network meta-analysis to compare the effectiveness and safety of the current three new types of hypoglycemic agents: dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists and sodium-dependent glucose transporters 2 inhibitors, to help clinicians and patients to choose which drug to use in different conditions. We'd like to conduct a network meta-analysis which is corrected by independent patient data to find out that if there is any difference between these current hypoglycemic agents in effectiveness and safety.

[{ "PostingID": 1612, "Title": "GSK-GLP108370", "Description": "An adaptive design study for the assessment of the pharmacokinetics of albiglutide in subjects with normal renal function and subjects with moderate-to-severe renal impairment and hemodialysis." },{ "PostingID": 1657, "Title": "GSK-GLP106073", "Description": "A single-blinded randomized, placebo-controlled, staggered-parallel, escalating-dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous injections of GSK 716155 in Subjects with type 2 Diabetes Mellitus" },{ "PostingID": 1659, "Title": "GSK-GLP105229", "Description": "A double-blinded, randomized, placebo-controlled, staggered-parallel, escalating dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous injections of GSK 716155 in healthy volunteers." },{ "PostingID": 1661, "Title": "GSK-GLP107085", "Description": "A Randomized, Double-blind, Parallel, Nested Crossover Study to Investigate the Effect of Albiglutide on Cardiac Repolarization (corrected QT Interval) Compared With Placebo in Healthy Male and Female Subjects: A Thorough ECG Study Employing Placebo, Albiglutide, and a Positive Control (Moxifloxacin)" },{ "PostingID": 1664, "Title": "GSK-GLP114179", "Description": "A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide in Subjects With Type 2 Diabetes Mellitus" },{ "PostingID": 1665, "Title": "GSK-GLP107724", "Description": "An Open-Label, Randomized, Multi-Site Study to Assess the Pharmacokinetics of Single Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered at Three Different Injection Sites in Adult Male and Female Subjects with Type 2 Diabetes and of Single Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered in the Abdomen of Healthy, Normal Volunteers" },{ "PostingID": 2414, "Title": "GSK-GLP110125", "Description": "A 16-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Doses and Multiple Treatment Regimens of GSK716155, with Byetta as an Open Label Active Reference, in Subjects with Type 2 Diabetes Mellitus" },{ "PostingID": 2415, "Title": "GSK-GLP114130", "Description": "A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Renal Impairment" },{ "PostingID": 2416, "Title": "GSK-GLP112753", "Description": "A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects With Type 2 Diabetes Mellitus" },{ "PostingID": 2422, "Title": "GSK-DPB100925", "Description": "A 12-Week, Parallel-Group, Double-Blind, Randomised, Placebo-Controlled, Multicentre, Dose Ranging Study toEvaluate the Efficacy, Safety and Tolerability of GW823093 (2.5mg, 7.5mg, 15mg, 30mg and 45mg), AdministeredOrally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus foll ..." },{ "PostingID": 2938, "Title": "GSK-GLP114856", "Description": "A multidose study in subjects with type 2 diabetes mellitus to assess the pharmacokinetics and pharmacodynamics of albiglutide" },{ "PostingID": 2952, "Title": "GSK-DPB102761", "Description": "An Open-Label Randomized Study with 3 Cohorts of 3-Way Crossovers to Investigate the Safety Tolerability and Pharmacokinetics of 45mg Oral Doses of GW823093C and 500mg BID Oral Doses of Metformin (Cohort 1) 8mg Oral Doses of Rosiglitazone (Cohort 2) and 45mg Oral Doses of Pioglitazone (Cohort 3)" },{ "PostingID": 3123, "Title": "GSK-GLP112754", "Description": "A randomized, open-label, parallel-group, multicenter study to determine the efficacy and long-term safety of albiglutide compared with insulin in subjects with type 2 diabetes mellitus." },{ "PostingID": 3124, "Title": "GSK-GLP112757", "Description": "A Randomized, Double-blind, Placebo and Active-Controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide Administered in Combination With Metformin and Glimepiride Compared With Metformin Plus Glimepiride and Placebo and with Metformin plus Glimepiride and Pioglitazone in Subjects With Type 2 Diabetes Mellitus" },{ "PostingID": 3125, "Title": "GSK-GLP108486", "Description": "A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared with the Combination of Insulin Glargine and Preprandial Lispro Insulin in Subjects With Type 2 Diabetes Mellitus" },{ "PostingID": 3126, "Title": "GSK-GLP112755", "Description": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Pioglitazone With or Without Metformin in Subjects with Type 2 Diabetes Mellitus" },{ "PostingID": 3127, "Title": "GSK-GLP108372", "Description": "A single-site, randomized, double-blind, placebo-controlled, parallel-group, stepped glucose clamp study to assess the effects of albiglutide on counter-regulatory hormone responses and recovery from hypoglycemia in subjects with Type 2 diabetes mellitus." },{ "PostingID": 3215, "Title": "ASTELLAS-1941-CL-0004", "Description": "A Phase 2, Double-Blind, Randomized, Placebo and Active-Controlled Dose-Finding Study to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of ASP1941 in Subjects with Type 2 Diabetes Mellitus" },{ "PostingID": 3216, "Title": "ASTELLAS-1941-CL-0005", "Description": "Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone" },{ "PostingID": 3544, "Title": "GSK-GPR111596", "Description": "A study in healthy volunteers of single doses of orally administered GSK1292263 to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of the compound alone and when co-administered with sitagliptin" },{ "PostingID": 3701, "Title": "GSK-GLP107865", "Description": "Clinical assessment of GSK716155 for Type 2 Diabetes Mellitus
 -A Phase I/II study to investigate the safety, pharmacokinetics and pharmacodynamics of GSK716155 in Japanese subjects with type 2 diabetes mellitus" },{ "PostingID": 3702, "Title": "GSK-GLP110932", "Description": "A Dose Finding Study of GSK716155 versus Placebo in the Treatment of Type 2 Diabetes Mellitus" },{ "PostingID": 3789, "Title": "GSK-HMD114728", "Description": "A multicenter, two part, randomized, parallel group, placebo and sitagliptin controlled study to evaluate the safety and efficacy of GSK256073 administered once or twice daily for 12 weeks in subjects with type 2 diabetes mellitus who are being treated with metformin" },{ "PostingID": 3936, "Title": "GSK-GLP112756", "Description": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Two Dose Levels of Albiglutide Compared With Placebo in Subjects With Type 2 Diabetes Mellitus" },{ "PostingID": 4217, "Title": "GSK-GLP113121", "Description": "A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects with Type 2 Diabetes Mellitus" },{ "PostingID": 4608, "Title": "ASTELLAS-1941-CL-0072", "Description": "Long-term Study of ASP1941 — Long-term Study in Patients with Type 2 Diabetes Mellitus with Decreased Renal Function (Japanese) —" },{ "PostingID": 4609, "Title": "ASTELLAS-1941-CL-0105", "Description": "Phase III Study of ASP1941 –A Phase III, Randomized, Double-Blind, Placebo-controlled, Monotherapy Study to Assess the Efficacy, Safety, and Tolerability of ASP1941 in Japanese Patients with Type 2 Diabetes Mellitus–" },{ "PostingID": 4610, "Title": "ASTELLAS-1941-CL-0106", "Description": "A Phase 3 Study to Assess the Efficacy and Safety of ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone" },{ "PostingID": 4611, "Title": "ASTELLAS-1941-CL-0107", "Description": "A Phase III Study to Assess the Efficacy, Safety and Tolerability of ASP1941 in Combination with Pioglitazone in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitazone Alone" },{ "PostingID": 4612, "Title": "ASTELLAS-1941-CL-0108", "Description": "Phase III Study of ASP1941 - Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Combination with an α-Glucosidase Inhibitor in Japanese Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control with an α-Glucosidase Inhibitor Alone" },{ "PostingID": 4613, "Title": "ASTELLAS-1941-CL-0109", "Description": "A Phase III Study to Assess the Efficacy, Safety and Tolerability of ASP1941 in Combination with Sulfonylurea in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea Alone" },{ "PostingID": 4614, "Title": "ASTELLAS-1941-CL-0110", "Description": "Phase III Study of ASP1941 - Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Combination with a Dipeptidyl Peptidase-4 Inhibitor in Japanese Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control with a Dipeptidyl Peptidase-4 Inhibitor Alone -" },{ "PostingID": 4615, "Title": "ASTELLAS-1941-CL-0111", "Description": "Phase III Study of ASP1941 - Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Combination with Nateglinide in Japanese Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control with Nateglinide Alone -" },{ "PostingID": 4616, "Title": "ASTELLAS-1941-CL-0121", "Description": "Long-term Study of ASP1941 - A Phase III, Open-Label, Uncontrolled, Monotherapy Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Japanese Patients with Type 2 Diabetes Mellitus -" },{ "PostingID": 4631, "Title": "GSK-GLP116170", "Description": "A 52-Week, Open-Label, Multicenter Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination with Monotherapy of Oral Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus" },{ "PostingID": 4711, "Title": "SANOFI-EFC6019", "Description": "A Randomized, Open-label, Active-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 Versus Exenatide on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin / GETGOAL-X" },{ "PostingID": 4712, "Title": "SANOFI-EFC6015", "Description": "A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of a Sulfonylurea in Patients With Type 2 Diabetes Not Adequately Controlled With Sulfonylurea / GETGOAL-S" },{ "PostingID": 4713, "Title": "SANOFI-LTS10888", "Description": "A Randomized, Open Label, Parallel-group (One-step Titration and Two-step Titration), Multicenter 52-Week Study Followed by a 24-Week Extension Assessing the Safety and Tolerability of AVE0010 Monotherapy in Patients With Type 2 Diabetes / GETGOAL-MONO Japan LTS" },{ "PostingID": 4714, "Title": "SANOFI-ACT6011", "Description": "Pharmacodynamics, safety, tolerability and pharmacokinetics following dose titration of
subcutaneously administered AVE0010 in patients with type 2 diabetes mellitus in a double-blind,
randomized, placebo-controlled Phase IIa study" },{ "PostingID": 4715, "Title": "SANOFI-PDY6797", "Description": "A randomized, double-blind, placebo-controlled, multinational study evaluating the safety and pharmacokinetics of 5 and 10 µg AVE0010 single doses and the efficacy, safety and pharmacokinetics of AVE0010 administered for 5 or 6 weeks, either once or twice daily, following dose escalation from 5 to 30 µg in Japanese and Caucasian type 2 diabetic patients not adequately controlled with sulfonylurea or sulfonylurea and metformin" },{ "PostingID": 4716, "Title": "SANOFI-PDY12625", "Description": "An Open-label, Randomized, Three-parallel-group Study on Pharmacodynamic Effects of 8-week QD Treatment With Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin" },{ "PostingID": 4717, "Title": "SANOFI-DRI6012", "Description": "A 13-week Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Trial Assessing the Safety, Tolerability and Efficacy of AVE0010 in Metformin-Treated Subjects with Type 2 Diabetes Mellitus" },{ "PostingID": 4718, "Title": "SANOFI-PDY10931", "Description": "An Open-label, Randomized Two-arm Parallel Group Study to Compare the Effects of 4-week QD Treatment With Lixisenatide or Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin" },{ "PostingID": 4719, "Title": "SANOFI-EFC10781", "Description": "A Randomized, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Double-blind Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine and Metformin / GetGoal Duo1" },{ "PostingID": 4720, "Title": "SANOFI-EFC12261", "Description": "A 24-week, Open-label, Randomized, 2-arm Parallel Group, Multinational, Multi-center Clinical Trial to Compare the Efficacy and Safety of Lixisenatide Injected Prior to the Main Meal of the Day Versus Lixisenatide Injected Prior to Breakfast in Type 2 Diabetic Patients Not Adequately Controlled on Metformin" },{ "PostingID": 4721, "Title": "SANOFI-EFC12626", "Description": "A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week Study Comparing the Efficacy and Safety of Lixisenatide to That of Insulin Glulisine Once Daily and Insulin Glulisine Three Times Daily in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine With or Without Metformin / GetGoal Duo-2" },{ "PostingID": 4722, "Title": "SANOFI-EFC6018", "Description": "A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter 12-week Study Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Not Treated With Antidiabetic Agents / GETGOAL-MONO" },{ "PostingID": 4723, "Title": "SANOFI-EFC10887", "Description": "A Randomized, Double-Blind, Placebo-Controlled, 2-arm Parallel-group, Multicenter Study With a 24-Week Treatment Period Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin With or Without Sulfonylurea / GETGOAL-L-Asia" },{ "PostingID": 4724, "Title": "SANOFI-EFC10743", "Description": "A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 in Two Titration Regimens on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin / GETGOAL-F1" },{ "PostingID": 4725, "Title": "SANOFI-EFC6016", "Description": "A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin / GETGOAL-L" },{ "PostingID": 4726, "Title": "SANOFI-EFC6014", "Description": "A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin / GETGOAL-M" },{ "PostingID": 4727, "Title": "SANOFI-EFC10780", "Description": "A Randomized, Double-blind, Double-dummy, 2-arm Parallel-group, Multicenter 24-week Study Comparing the Efficacy and Safety of AVE0010 to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 and Not Adequately Controlled With Metformin" },{ "PostingID": 4728, "Title": "SANOFI-EFC6017", "Description": "A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Pioglitazone in Patients With Type 2 Diabetes Not Adequately Controlled With Pioglitazone / GETGOAL-P" },{ "PostingID": 4729, "Title": "SANOFI-EFC11321", "Description": "Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin (With or Without Sulfonylurea): a Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study With 24-week Treatment Period / GetGoal-M-Asia" },{ "PostingID": 4730, "Title": "SANOFI-EFC11319", "Description": "A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome / ELIXA" },{ "PostingID": 4767, "Title": "SANOFI-ACT12374", "Description": "A Randomized, 24-week, Open-label, 2-arm Parallel-group, Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine on Top of Metformin in Type 2 Diabetic Patients" },{ "PostingID": 4768, "Title": "SANOFI-EFC12404", "Description": "A Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to Lixisenatide Alone on Top of Metformin in Patients With Type 2 Diabetes Mellitus (T2DM) / LixiLan-O" },{ "PostingID": 4769, "Title": "SANOFI-EFC12405", "Description": "A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus (T2DM) / LixiLan-L" },{ "PostingID": 4776, "Title": "GSK-GHF112670", "Description": "A multi-center, placebo-controlled study to evaluate the safety of GSK716155 and its effects on myocardial metabolism, myocardial function, and exercise capacity in patients with NYHA Class II/III congestive heart failure" },{ "PostingID": 4831, "Title": "ASTELLAS-1941-CL-0131", "Description": "Postmarketing Clinical Study of Ipragliflozin - Double-blind, Parallel-group Study in Combination with Insulin in Patients with Type 2 Diabetes Mellitus -" },{ "PostingID": 4954, "Title": "GSK-200016", "Description": "An Open-Label Exploratory Study to Investigate the Feasibility of Administering Exenatide by Continuous Subcutaneous Infusion to Healthy Subjects" },{ "PostingID": 5021, "Title": "GSK-201834", "Description": "A randomized, double-blind, single-dose, placebo controlled, 2-way cross-over study evaluating effect of albiglutide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects" },{ "PostingID": 14553, "Title": "GSK-201840", "Description": "An Exploratory Randomized, 2-Part, Single-blind, 2-Period Crossover Study Comparing the Effect of Albiglutide with Exenatide on Regional Brain Activity Related to Nausea in Healthy Volunteers" },{ "PostingID": 14555, "Title": "GSK-204879", "Description": "A Randomized, Open-label, Active-Controlled, Parallel-Group, Exploratory Study on the Effects of Repeated Doses of Albiglutide compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Subjects with Type 2 Diabetes Mellitus" },{ "PostingID": 19519, "Title": "SANOFI-EFC12382", "Description": "A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin With or Without Metformin" },{ "PostingID": 19520, "Title": "SANOFI-SFY13476", "Description": "An Open-label, Multicenter 24-Week and 52-Week Study Assessing the Safety and
Tolerability of Lixisenatide in Monotherapy in Patients with Type 2 Diabetes" },{ "PostingID": 19521, "Title": "SANOFI-LTS12809", "Description": "An Open-Label, Multicenter 52-Week Study Assessing the Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes" },{ "PostingID": 19522, "Title": "SANOFI-LIXISL06651", "Description": "A Randomized, Multicenter, Open-Label, Parallel-Group, 28 Days Phase IV Study Comparing The Postprandial Plasma Glucose Profile of Lixisenatide With That of Sitagliptin Add-On to Insulin Glargine in Type 2 Diabetes Mellitus" },{ "PostingID": 19588, "Title": "GSK-201287", "Description": "A Randomized, Double-blind, Single-dose, Crossover Study to Compare Two Albiglutide Drug Products for Bioequivalence in Healthy Adult Subjects" },{ "PostingID": 19799, "Title": "GSK-GLP116174", "Description": "A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with Type 2 diabetes mellitus" },{ "PostingID": 19894, "Title": "GSK-204682", "Description": "An Open-label Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Subjects with Type 2 Diabetes Mellitus" },{ "PostingID": 19895, "Title": "GSK-200952", "Description": "A Repeat-dose Study in Subjects with Type 2 Diabetes Mellitus to Assess the Efficacy, Safety, Tolerability and Pharmacodynamics, of Albiglutide Liquid Drug Product" }]